| Product Code: ETC13140300 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global mRNA Therapeutics Contract Development & Manufacturing Organization Market was valued at USD 5.5 Billion in 2024 and is expected to reach USD 12.5 Billion by 2031, growing at a compound annual growth rate of 12.60% during the forecast period (2025-2031).
The Global mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) market is experiencing significant growth due to the increasing demand for mRNA-based therapies. CDMOs play a crucial role in providing end-to-end services for the development and manufacturing of mRNA therapeutics, including formulation development, process optimization, and scale-up manufacturing. The market is driven by the rising investments in mRNA technology, collaborations between pharmaceutical companies and CDMOs, and the need for specialized expertise in mRNA production. Key players in the market are expanding their capabilities to meet the growing demand, offering advanced technologies and flexible manufacturing solutions to support the development of mRNA therapies for various diseases. The market is expected to continue its growth trajectory as mRNA therapeutics gain momentum in the biopharmaceutical industry.
The Global mRNA Therapeutics Contract Development & Manufacturing Organization Market is experiencing significant growth due to the increasing demand for mRNA-based therapeutics, particularly in the field of infectious diseases, cancer, and rare genetic disorders. The COVID-19 pandemic has accelerated the adoption of mRNA technology, leading to a surge in research and development activities. Key trends in the market include strategic partnerships and collaborations between pharmaceutical companies and CDMOs to enhance manufacturing capabilities and meet the growing demand for mRNA therapeutics. Additionally, advancements in mRNA technology, such as lipid nanoparticle delivery systems and personalized medicine approaches, are driving innovation in the market. Opportunities for CDMOs lie in expanding their manufacturing capacities, investing in cutting-edge technologies, and providing end-to-end services to cater to the evolving needs of pharmaceutical clients in the mRNA therapeutics space.
The Global mRNA Therapeutics Contract Development & Manufacturing Organization Market faces various challenges, including the need for specialized expertise and infrastructure to manufacture mRNA therapeutics at scale, ensuring regulatory compliance and quality control throughout the manufacturing process, managing the complex supply chain for raw materials, and addressing the high costs associated with developing and manufacturing mRNA therapies. Additionally, the rapid pace of technological advancements in the mRNA field requires CDMOs to continuously invest in cutting-edge technologies and stay ahead of the competition. Furthermore, navigating intellectual property rights and collaborations with pharmaceutical companies adds another layer of complexity to the market landscape. Overall, overcoming these challenges will be crucial for CDMOs to capitalize on the growing demand for mRNA therapeutics and establish a strong foothold in the market.
The Global mRNA Therapeutics Contract Development & Manufacturing Organization Market is primarily driven by the increasing demand for mRNA-based therapeutics due to their potential in treating various diseases, including cancer, infectious diseases, and genetic disorders. The advancements in mRNA technology, such as improved delivery systems and increased understanding of mRNA mechanisms, have also fueled market growth. Additionally, the growing number of collaborations between pharmaceutical companies and contract development and manufacturing organizations (CDMOs) to expedite the development and production of mRNA therapeutics is a significant driver. Furthermore, the favorable regulatory environment and government support for mRNA-based therapies are expected to further boost market expansion in the coming years.
Government policies related to the Global mRNA Therapeutics Contract Development & Manufacturing Organization Market aim to promote innovation, ensure product quality and safety, and facilitate market access. These policies often include regulatory frameworks governing the development, manufacturing, and distribution of mRNA therapeutics, as well as incentives to encourage investment in research and development. Additionally, governments may provide funding for infrastructure development and support collaborations between industry stakeholders and academic institutions to advance the field. Overall, the regulatory environment seeks to balance the need for robust oversight with fostering a competitive and dynamic marketplace for mRNA therapeutics, ultimately driving growth and accessibility in the sector.
The Global mRNA Therapeutics Contract Development & Manufacturing Organization Market is poised for significant growth in the coming years. With the increasing focus on personalized medicine and the development of mRNA-based therapies for various diseases such as cancer, infectious diseases, and genetic disorders, the demand for contract development and manufacturing organizations specializing in mRNA therapeutics is expected to surge. Additionally, the success of mRNA vaccines against COVID-19 has boosted confidence in the technology, leading to more investment and collaborations in this space. As pharmaceutical companies continue to explore the potential of mRNA therapeutics, CDMOs offering expertise in mRNA manufacturing and development are likely to play a crucial role in accelerating the translation of these therapies from the lab to the clinic, driving the growth of the market.
In the global mRNA therapeutics contract development and manufacturing organization market, North America holds the largest share due to the presence of established pharmaceutical companies and biotech firms investing heavily in mRNA technology. Europe follows closely behind with a growing emphasis on personalized medicine and advancements in mRNA research. Asia is experiencing rapid growth in the market, driven by increasing investments in healthcare infrastructure and rising demand for innovative therapies. The Middle East and Africa region is also witnessing a surge in mRNA therapeutics development, supported by government initiatives and collaborations with international players. Latin America is poised for significant growth, with a burgeoning biopharmaceutical industry and a growing focus on precision medicine driving the demand for mRNA CDMO services.
Global mRNA Therapeutics Contract Development & Manufacturing Organization Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, 2021 & 2031F |
3.3 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market - Industry Life Cycle |
3.4 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market - Porter's Five Forces |
3.5 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Trends |
6 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, 2021 - 2031 |
6.1 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Application, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Viral Vaccines, 2021 - 2031 |
6.1.3 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Protein Replacement Therapies, 2021 - 2031 |
6.1.4 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Cancer Immunotherapies, 2021 - 2031 |
6.2 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Infectious Diseases, 2021 - 2031 |
6.2.3 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Metabolic & Genetic Diseases, 2021 - 2031 |
6.2.4 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Cardiovascular & Cerebrovascular Diseases, 2021 - 2031 |
6.3.1 Overview & Analysis |
7 North America mRNA Therapeutics Contract Development & Manufacturing Organization Market, Overview & Analysis |
7.1 North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
7.2 North America mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
7.3 North America mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Application, 2021 - 2031 |
7.4 North America mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
8 Latin America (LATAM) mRNA Therapeutics Contract Development & Manufacturing Organization Market, Overview & Analysis |
8.1 Latin America (LATAM) mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Application, 2021 - 2031 |
8.4 Latin America (LATAM) mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
9 Asia mRNA Therapeutics Contract Development & Manufacturing Organization Market, Overview & Analysis |
9.1 Asia mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
9.2 Asia mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Application, 2021 - 2031 |
9.4 Asia mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
10 Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market, Overview & Analysis |
10.1 Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
10.2 Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Application, 2021 - 2031 |
10.4 Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
11 Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market, Overview & Analysis |
11.1 Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
11.2 Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Application, 2021 - 2031 |
11.4 Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
12 Middle East mRNA Therapeutics Contract Development & Manufacturing Organization Market, Overview & Analysis |
12.1 Middle East mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Application, 2021 - 2031 |
12.4 Middle East mRNA Therapeutics Contract Development & Manufacturing Organization Market, Revenues & Volume, By Indication, 2021 - 2031 |
13 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Key Performance Indicators |
14 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market - Export/Import By Countries Assessment |
15 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market - Opportunity Assessment |
15.1 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Opportunity Assessment, By Application, 2021 & 2031F |
15.3 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Opportunity Assessment, By Indication, 2021 & 2031F |
16 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market - Competitive Landscape |
16.1 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Revenue Share, By Companies, 2024 |
16.2 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |